Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET
Abstract
We recently identified CD46 as a novel therapeutic target in prostate cancer. In this study, we developed a CD46-targeted PET radiopharmaceutical, [89Zr]DFO-YS5, and evaluated its performance for immunoPET imaging in murine prostate cancer models.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-3310
Entities
People
- Bin Liu
- Daniel Gioeli
- Denis R Beckford-Vera
- Emily A. Egusa
- Felix Y. Feng
- Fujun Qin
- Jiang He
- Jonathan Chou
- Jun Hua
- Jun Li
- Mayuri Jayaraman
- Michael J Evans
- Ning Zhao
- Rahul Aggarwal
- Renuka Sriram
- Robert Dreicer
- Robert R Flavell
- Sinan Wang
- Sui Shen
- Tony Huynh
- Walter Zhao
- Yang Su
- Yangjie Huang
- Youngho Seo
Organizations
- Chongqing University
- Fudan University
- National Cancer Institute
- National Institutes of Health
- University of Alabama at Birmingham
- University of California
- University of California, San Francisco
- University of Virginia